FDA Accepts Milestone Pharmaceuticals' New Drug Application For Cardamyst (Etripamil) Nasal Spray, To Manage Paroxysmal Supraventricular Tachycardia Prescription Drug User Fee Act Is 10 Months From The Acceptance Date Of May 26, 2024

5/29/24 7:05:19 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MIST alert in real time by email

Get the next $MIST alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MIST

Date	Price Target	Rating	Analyst
8/22/2024	$9.00	Buy	Rodman & Renshaw
6/20/2023	$8.00 → $4.00	Buy → Hold	Jefferies
4/22/2022	$8.00 → $10.00	Neutral → Overweight	Piper Sandler

More analyst ratings

$MIST
Press Releases

Fastest customizable press release news feed in the world

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. "Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT," said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. "We believe that CARDAMYST has the potential to improve how PSVT is managed and positions Milestone to deliver meaningful value to patients, providers, and payors. Complementing our efforts in PSVT, we are very encouraged by clinician interest in
11/12/24 9:03:05 AM ET
$MIST
Biotechnology: Pharmaceutical Preparations
Health Care
Milestone Pharmaceuticals to Host Investor KOL Event
Learnings from the Field: Managing PSVT and Studying AFib-RVR in the Community Setting Hosted 10 am ET, Tuesday, October 8, 2024 MONTREAL and CHARLOTTE, N.C., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced it will host Part 2 of its virtual investor education series on Tuesday, October 8, 2024 from 10:00 AM ET to 11:30 AM ET. To register for "Learnings from the Field: Expert Perspectives on Managing PSVT and Studying AFib-RVR in the Community Setting", click here. The event will feature Aamer H. Jamali MD, FAC
9/24/24 8:00:00 AM ET
$MIST
Biotechnology: Pharmaceutical Preparations
Health Care
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing Pharmaceuticals Ltd, released positive topline results from a multi-center, randomized, double-blind, placebo-controlled trial in China evaluating the efficacy and safety of etripamil nasal spray in paroxysmal supraventricular tachycardia (PSVT). The trial design closely matched the RAPID Phase 3 Study of etripamil in PSVT conducted by Milestone in North America and Europe. The 500-patient Phase 3 trial (JX02002) me
9/6/24 7:00:00 AM ET
$MIST
Biotechnology: Pharmaceutical Preparations
Health Care

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro
9/4/24 8:00:00 AM ET
$CADL
$EBS
$MIST
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update
- RAPID topline data readout remains on track for mid-second half 2022 - Results from NODE-302 study highlights etripamil safety and reduced need for ED interventions MONTREAL and CHARLOTTE, N.C., May 12, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2022, and provided a clinical and corporate update. "The beginning of 2022 has been a productive time for Milestone, marked by continued progress advancing our lead Phase 3 program, etripamil, for patients with PSVT," said Josep
5/12/22 7:15:00 AM ET
$MIST
Biotechnology: Pharmaceutical Preparations
Health Care
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update
- RAPID topline data readout expected mid-second half 2022 MONTREAL and CHARLOTTE, N.C., March 24, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a clinical and corporate update. "2021 was a year of focused execution across our ongoing clinical programs which are evaluating etripamil in patients with PSVT and AFib-RVR," said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. "We are well-positioned for a transformat
3/24/22 7:20:00 AM ET
$MIST
Biotechnology: Pharmaceutical Preparations
Health Care

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, for patients with PSVT Positive Phase 2 data evaluating etripamil in AFib-RVR were a Featured Science Presentation at 2023 AHA Scientific Sessions; Phase 3 program expected to begin enrollment in mid-2024Company to host Investor and Analyst Webcast to review data from ReVeRA Phase 2 study of etripamil in atrial fibrillation with rapid ventricular rate today at 8:00 a.m. ETMONTREAL and CHARLOTTE, N.C., Nov. 13, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today reported financial results for the third quarter ended Septem
11/13/23 6:57:00 AM ET
$MIST
Biotechnology: Pharmaceutical Preparations
Health Care
Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate
- Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes - Data featured in an oral session at the Heart Rhythm 2023 Annual Meeting - Company to host virtual KOL conference call and webcast to discuss etripamil development for the treatment of AFib-RVR today at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., May 22, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced promising data from an ad hoc analysis of a subset of patients experien
5/22/23 7:00:00 AM ET
$MIST
Biotechnology: Pharmaceutical Preparations
Health Care
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate
- Cardiac Electrophysiology Key Opinions Leaders to include Paul Dorian, MD, and Jonathan Piccini, MD - Conference call and webcast on Monday, May 22, 2023 at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., May 8, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Monday, May 22, 2023 at 8:00 a.m. ET. The event will focus on etripamil, the Company's lead investigational product, for the potential treatment of patients with atrial fibrillation (AFib) and rapid ventricular rate (A
5/8/23 7:00:00 AM ET
$MIST
Biotechnology: Pharmaceutical Preparations
Health Care

FDA Accepts Milestone Pharmaceuticals' New Drug Application For Cardamyst (Etripamil) Nasal Spray, To Manage Paroxysmal Supraventricular Tachycardia Prescription Drug User Fee Act Is 10 Months From The Acceptance Date Of May 26, 2024

Chat with this insight

Recent Analyst Ratings for $MIST

$MIST SEC Filings

SEC Form S-3 filed by Milestone Pharmaceuticals Inc.

SEC Form S-8 filed by Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$MIST Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target

HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target

FDA Accepts Milestone Pharmaceuticals' New Drug Application For Cardamyst (Etripamil) Nasal Spray, To Manage Paroxysmal Supraventricular Tachycardia Prescription Drug User Fee Act Is 10 Months From The Acceptance Date Of May 26, 2024

$MIST Press Releases

Fastest customizable press release news feed in the world

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals to Host Investor KOL Event

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

$MIST Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Papa Joseph C

SEC Form 3 filed by new insider Papa Joseph C

SEC Form 4 filed by Director Giles Lisa M.

$MIST Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Milestone Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc. (Amendment)

$MIST Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on Milestone Pharmaceuticals with a new price target

Milestone Pharmaceuticals downgraded by Jefferies with a new price target

Milestone Pharmaceuticals upgraded by Piper Sandler with a new price target

$MIST Leadership Updates

Live Leadership Updates

$MIST Financials

Live finance-specific insights

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate

Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate

Recent Analyst Ratings for
$MIST

$MIST
SEC Filings

$MIST
Market Insights

$MIST
Press Releases

$MIST
Insider Trading

$MIST
Large Ownership Changes

$MIST
Analyst Ratings

$MIST
Leadership Updates

$MIST
Financials